Nonalcoholic steatohepatitis, insulin resistance, and metabolic syndrome: further evidence for an etiologic association. - sprookjes - yvandenbroek - TriplyDB

Nonalcoholic steatohepatitis, insulin resistance, and metabolic syndrome: further evidence for an etiologic association.

Nonalcoholic steatohepatitis, insulin resistance, and metabolic syndrome: further evidence for an etiologic association.

http://www.wikidata.org/entity/Q34112671

about

Hepatic steatosis: a benign disease or a silent killer The Pathogenesis of Nonalcoholic Fatty Liver Disease: Interplay between Diet, Gut Microbiota, and Genetic Background Lifestyle changes for the treatment of nonalcoholic fatty liver disease: a review of observational studies and intervention trials Gut Microbiota and Lifestyle Interventions in NAFLD Relevant Aspects of Nutritional and Dietary Interventions in Non-Alcoholic Fatty Liver Disease Nonalcoholic Fatty liver disease and risk of diabetes and cardiovascular disease: what is important for primary care physicians?Dietary habits and behaviors associated with nonalcoholic fatty liver disease Fructose as a key player in the development of fatty liver disease Low-normal thyroid function and novel cardiometabolic biomarkers Hepatic steatosis, detected by hepatorenal index in ultrasonography, as a predictor of insulin resistance in obese subjects Eriocitrin ameliorates diet-induced hepatic steatosis with activation of mitochondrial biogenesis.Mild electrical stimulation with heat shock ameliorates insulin resistance via enhanced insulin signaling.Impact of resistant starch on body fat patterning and central appetite regulation.Risk factors associated with non-alcoholic fatty liver disease in subjects from primary care units. A case-control study Metformin in nonalcoholic steatohepatitis: a randomized controlled trial Modification of a simple clinical scoring system as a diagnostic screening tool for non-alcoholic steatohepatitis in Japanese patients with non-alcoholic fatty liver disease.Biphasic response of mitochondrial biogenesis to oxidative stress in visceral fat of diet-induced obesity mice.Role of serotonin in fatty acid-induced non-alcoholic fatty liver disease in mice.Nonalcoholic fatty liver disease and serum lipoproteins: the Multi-Ethnic Study of Atherosclerosis.Inflammatory mediators of hepatic steatosis.Prevalence of metabolic syndrome among adults with liver function injury in rural area of Southwest China: A cross-sectional study.Non-high-density lipoprotein cholesterol (non-HDL-C) levels in children with nonalcoholic fatty liver disease (NAFLD)Pioglitazone versus vitamin E versus placebo for the treatment of non-diabetic patients with non-alcoholic steatohepatitis: PIVENS trial design.Non-alcoholic steatohepatitis and influence of age and gender on histopathologic findings Treatment of nonalcoholic fatty liver disease in children: TONIC trial design.Serum uric Acid as a predictor for the development of nonalcoholic Fatty liver disease in apparently healthy subjects: a 5-year retrospective cohort study.Regulatable fatty acid transport mechanisms are central to the pathophysiology of obesity, fatty liver, and metabolic syndrome.Disordered lipid metabolism and the pathogenesis of insulin resistance.Cardiovascular risk factors and the metabolic syndrome in pediatric nonalcoholic fatty liver disease Intervention with a caspase-1 inhibitor reduces obesity-associated hyperinsulinemia, non-alcoholic steatohepatitis and hepatic fibrosis in LDLR-/-.Leiden mice.Interaction of obesity, metabolic syndrome and Framingham risk on steatohepatitis among healthy Taiwanese: population-based nested case-control study.Metabolic syndrome in the pediatric population: a short overview Nonalcoholic steatohepatitis: what we know in the new millennium.The pathophysiology of obesity and its clinical manifestations.The role of insulin-sensitizing agents in the treatment of nonalcoholic steatohepatitis.Effects of metformin and weight loss on serum alanine aminotransferase activity in the diabetes prevention program Evaluation of the immune response to pneumococcal capsular polysaccharides.Nutrition and physical activity in NAFLD: an overview of the epidemiological evidence.Obesity, Visceral Fat, and NAFLD: Querying the Role of Adipokines in the Progression of Nonalcoholic Fatty Liver Disease.Noninvasive predictors for liver fibrosis in patients with nonalcoholic steatohepatitis.

P2860

Q22305506-3682729A-1003-43F8-8B66-9C91B9FF3855 Q26744380-7E3FB3DF-EBA0-48DD-8BD1-4D7514D914F2 Q26748608-549AED36-81A5-429D-AC36-AA437BEACAB7 Q26749783-B2013237-7A5A-450E-859F-0542459A1A90 Q26778020-83EA92F9-4063-4059-AD3B-D0F15AD72336 Q26827169-093CA503-29A9-4995-8D25-FBF500360FF1 Q26830594-7B3E49C4-B79D-46B7-B31D-EE78B2E1B022 Q27014596-648A39BF-47C5-4D86-A0B0-BE45D8EA595E Q28084990-1CB83E44-B0A3-49DC-8400-3E5CEA471F90 Q28595534-48E435EE-E412-46AE-BA97-5F09423D0EF2 Q30564438-D84594B1-0CC4-4197-8570-9E381B539FBB Q30856517-23D24160-51FB-4D40-B2DA-5340A8CAA804 Q33309957-8844DBB8-8C47-4DB7-BFAA-8904D37E0F7F Q33373532-D59FDF88-F6A9-479D-8BC0-5169846B867E Q33597395-4FF8DF3B-E63E-42B0-A837-45B26CE96898 Q33607793-CB315C3F-D95E-4C2E-8FEF-822E16639298 Q33630100-0A1A3E6B-9850-4DCC-872D-E1555AB384D6 Q33645106-5B0D171E-7D29-4778-8E1D-F65CE9A7A944 Q33724815-D119FEE6-1765-48BD-BC9D-17826DF239A7 Q33734136-653A0871-4B9C-4A63-875C-FA70E99EF74F Q33912265-99767EC1-82F3-45A7-86B7-2515DF6D6034 Q34037347-FC12B672-665B-41DF-827C-ADABB3A9C896 Q34090872-302982A1-F290-47FC-AACA-C1783488134D Q34102001-A20D7894-34C7-4FF7-9874-C4684ED065D5 Q34114795-01A0EB7D-1AA5-4052-BC02-048955309412 Q34206710-AA81048F-7547-46E5-9751-65528F934F86 Q34207748-8957B425-C528-42B7-8E1B-188E31B736D5 Q34370965-1156A911-EAE1-4CE7-8DBD-3E55DAF8BDDD Q34378263-FD129AE6-51AE-4598-A0B5-B6401422DF27 Q34523876-DB428A41-1C4E-4EB3-BAEB-538E6DBD9292 Q34690842-8172E273-F481-45C9-95A5-E6EDE5826964 Q34985768-9CD7884E-3AD6-48CB-A22E-6038BDC76BD0 Q34993711-226870E2-DF66-4119-A80A-CCB0F665580F Q35013868-1D3ED8DF-1D67-463E-B195-CEB413775900 Q35090416-AB334256-1F23-4B3A-8B6B-AAA78ABBC338 Q35101309-942E6332-CE0B-4D25-82A2-E77774A4E3FE Q35167055-E9171B66-C4F7-433F-84E2-2807DE55295C Q35178073-F5F8223B-B24F-4BD2-9F6D-57384A59FE09 Q35200808-4DF168F6-C1CC-48A9-A96E-331B28F8A5CE Q35233535-EC81C31E-CD28-4CB3-943F-C0A4B6F7D491

P2860

Nonalcoholic steatohepatitis, insulin resistance, and metabolic syndrome: further evidence for an etiologic association.

http://www.wikidata.org/entity/Q34112671

description

2002 nî lūn-bûn

@nan

2002 թուականի Փետրուարին հրատարակուած գիտական յօդուած

@hyw

2002 թվականի փետրվարին հրատարակված գիտական հոդված

@hy

2002年の論文

@ja

2002年論文

@yue

2002年論文

@zh-hant

2002年論文

@zh-hk

2002年論文

@zh-mo

2002年論文

@zh-tw

2002年论文

@wuu

name

Nonalcoholic steatohepatitis, ...... for an etiologic association.

@ast

Nonalcoholic steatohepatitis, ...... for an etiologic association.

@en

Nonalcoholic steatohepatitis, ...... for an etiologic association.

@nl

type

label

Nonalcoholic steatohepatitis, ...... for an etiologic association.

@ast

Nonalcoholic steatohepatitis, ...... for an etiologic association.

@en

Nonalcoholic steatohepatitis, ...... for an etiologic association.

@nl

prefLabel

Nonalcoholic steatohepatitis, ...... for an etiologic association.

@ast

Nonalcoholic steatohepatitis, ...... for an etiologic association.

@en

Nonalcoholic steatohepatitis, ...... for an etiologic association.

@nl

P1433

Q34112671-0DADC9AA-27A6-432D-9603-E3653B9B25D1

P1476

Q34112671-2E373192-F9BC-4AC9-B090-DD8A79D972CD

P2093

Q34112671-0B590A4F-42EA-47B1-BBB2-9F78C2176ADA

Q34112671-10688AA9-C216-4E33-8950-369F1F14E683

Q34112671-12143168-2A4E-4AFD-B7D1-E3B8E152A3CD

Q34112671-3B64B1E3-2846-4C28-AFB8-1F5416478482

Q34112671-57228AB1-D24D-43D4-8AF9-F298DD3F0511

Q34112671-74F4FFAB-06E4-4BD9-96B7-498F016D9528

Q34112671-A19CE5A2-6479-4B2A-AE41-2D9EE512DE9D

Q34112671-BCBF67FA-5DEF-4254-807C-2CEE5031C994

Q34112671-C93D21CB-F14D-49BA-B05C-B681BA314CD0

Q34112671-DE4AA998-E324-4989-8B00-9FADE9B390B8

P2860

Q34112671-122B2934-B54C-4350-BA52-186730F64A71

Q34112671-170D2E25-4A29-475D-A760-7259AC401EB4

Q34112671-25B8714E-0D00-4B86-A1D4-8FD44E49C66D

Q34112671-3587CEF3-83DE-4D6C-BDBA-8F1A510330A2

Q34112671-3DF962B5-960B-4046-89D2-94D491E546E4

Q34112671-49ACE4C3-4343-4702-8B2B-0FC1EB233F4B

Q34112671-5EBB0C0A-C364-410D-B796-E5D0CBDE6401

Q34112671-6C3AE8FE-D3C4-47E7-980F-225A9507ED88

Q34112671-7C943FF0-8E40-4D52-84C8-74E93E4ED565

Q34112671-8A68523F-E0FA-47BB-A443-26AE0921B54E

P304

Q34112671-D34D25E4-930E-403A-BF78-C27D62CDEF15

P31

Q34112671-F00871F5-5031-42A0-A231-6517047830BD

P356

Q34112671-A8B1A652-5B3A-4955-8EF9-85166FAC544A

P407

Q34112671-838E8C45-A44A-40C4-BD8A-DF6DB8F595D9

P433

Q34112671-81EE6879-36B8-4517-9743-A640594F94B6

P478

Q34112671-9A21F83A-B959-4BC5-A781-31FCB15851B0

P577

Q34112671-D4293E66-2B60-4F22-A06B-33FDB26E8564

P5875

Q34112671-47FDB15A-4319-4430-B5E7-A03CDE1526B4

P698

Q34112671-FECD4774-9FD6-4288-A953-DE16B22A29BD

P921

Q34112671-1836B9AF-68BC-499E-B2EE-F76FE4910D97

Q34112671-6F3F5A15-5FF2-42A5-82E8-E2256E8C575E

Q34112671-D186DC7A-C19B-454B-8655-F13C9CF1C4E7

P356

JHEP.2002.30690

P1433

P1476

Nonalcoholic steatohepatitis, ...... for an etiologic association.

@en

P2093

Ezio David

http://www.w3.org/2001/XMLSchema#string

Fabio Mecca

http://www.w3.org/2001/XMLSchema#string

Gianfranco Pagano

http://www.w3.org/2001/XMLSchema#string

Giovanni Musso

http://www.w3.org/2001/XMLSchema#string

Giovanni Pacini

http://www.w3.org/2001/XMLSchema#string

Mario Rizzetto

http://www.w3.org/2001/XMLSchema#string

Maurizio Cassader

http://www.w3.org/2001/XMLSchema#string

Nadia Depetris

http://www.w3.org/2001/XMLSchema#string

Paolo Cavallo-Perin

http://www.w3.org/2001/XMLSchema#string

Roberto Gambino

http://www.w3.org/2001/XMLSchema#string

P2860

Comparison of insulin sensitivity tests across a range of glucose tolerance from normal to diabetes

Idiopathic steatohepatitis in childhood: a multicenter retrospective study

Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation

Steatohepatitis: a tale of two "hits"?

Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity

Cryptogenic cirrhosis: clinical characterization and risk factors for underlying disease.

A pilot study of a thiazolidinedione, troglitazone, in nonalcoholic steatohepatitis.

Nonalcoholic steatohepatitis.

Physiologic evaluation of factors controlling glucose tolerance in man: measurement of insulin sensitivity and beta-cell glucose sensitivity from the response to intravenous glucose.

Lilly lecture 1989. Toward physiological understanding of glucose tolerance. Minimal-model approach.

P304

367-372

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1053/JHEP.2002.30690

http://www.w3.org/2001/XMLSchema#string

P407

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

35

http://www.w3.org/2001/XMLSchema#string

P577

2002-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

11534703

http://www.w3.org/2001/XMLSchema#string

P698

11826410

http://www.w3.org/2001/XMLSchema#string

P921

Steatohepatitis

metabolic syndrome